These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17499539)

  • 1. [Plasma fractionation in the world: current status].
    Burnouf T
    Transfus Clin Biol; 2007 May; 14(1):41-50. PubMed ID: 17499539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current strategies to prevent transmission of prions by human plasma derivatives.
    Burnouf T; Padilla A
    Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma protein therapies: current and future perspectives.
    Farrugia A; Robert P
    Best Pract Res Clin Haematol; 2006; 19(1):243-58. PubMed ID: 16377552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
    Flan B; Arrabal S
    Transfus Clin Biol; 2007 May; 14(1):51-62. PubMed ID: 17540602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.
    Farrugia A; Ironside JW; Giangrande P
    Vox Sang; 2005 Nov; 89(4):186-92. PubMed ID: 16262750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Product delivery in the developing world: options, opportunities and threats.
    Farrugia A
    Haemophilia; 2004 Oct; 10 Suppl 4():77-82. PubMed ID: 15479376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.
    Cheraghali AM; Aboofazeli R
    Transfus Med; 2009 Dec; 19(6):363-8. PubMed ID: 19778319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
    Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
    Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Norwegian Plasma Fractionation Project--a 12 year clinical and economic success story.
    Flesland O; Seghatchian J; Solheim BG
    Transfus Apher Sci; 2003 Feb; 28(1):93-100. PubMed ID: 12620274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and supply of haemophilia products: worldwide perspectives.
    Farrugia A
    Haemophilia; 2004 Jul; 10(4):327-33. PubMed ID: 15230945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Products for clotting factor replacement in developing countries.
    Kasper CK
    Semin Thromb Hemost; 2005 Nov; 31(5):507-12. PubMed ID: 16276458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory challenges to global harmonization and expanded access to concentrates: how will regulators balance the increasing cost of new safety requirements with the desire to increase the availability of affordable product?
    Farrugia A
    Haemophilia; 2004 Oct; 10 Suppl 4():83-7. PubMed ID: 15479377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogen reduction of blood components.
    Solheim BG
    Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dynamics of contract plasma fractionation.
    Farrugia A; Scaramuccia D
    Biologicals; 2017 Mar; 46():159-167. PubMed ID: 28236560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International movement of plasma and plasma contracting.
    Farrugia A
    Dev Biol (Basel); 2005; 120():85-96. PubMed ID: 16050160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasma fractionation. Progress, problems and perspectives].
    Burnouf T
    Ann Pharm Fr; 1994; 52(3):124-36. PubMed ID: 7998759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma for fractionation: safety and quality issues.
    Farrugia A
    Haemophilia; 2004 Jul; 10(4):334-40. PubMed ID: 15230946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clearance of prions during plasma protein manufacture.
    Burdick MD; Pifat DY; Petteway SR; Cai K
    Transfus Med Rev; 2006 Jan; 20(1):57-62. PubMed ID: 16373188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.